Background: Diabetes mellitus is a major health problem worldwide with long-term micro-and macrovascular complications responsible for a majority of its morbidity and mortality. The development and progression of these complications relate strongly to glycemic control. Methods: We reviewed the literature extensively for studies that relate glycemic control to the development and progression of diabetic complications. We discuss the problems of standardizing glycohemoglobin measurements for monitoring diabetic therapy and also consider recently developed electrospray ionization mass spectrometry methods that have been considered as candidate reference methods for estimation of glycohemoglobin. Results: Several clinical trials and studies have clearly shown that improved glycemic control is strongly associated with decreased development and/or progression of complications in both type 1 and type 2 diabetes mellitus. Irrespective of the methods used for estimating glycohemoglobin, these results underline the importance of glycohemoglobin for guiding therapy of diabetes mellitus. Recently developed candidate reference methods promise to yield greatly improved standardization for the measurement of glycohemoglobin. Conclusions: Glycohemoglobin measurement remains the optimal indicator of glycemic control in diabetic patients, but translation of findings from clinical trials to clinical practice worldwide demands consistent values across all assays. To ensure that the important prognostic information still applies to all diabetic patients with the application of the reference method(s), the hemoglobin A 1c values reported in the major clinical trials will have to be translated into statistically and
Over the past several decades, diabetes mellitus has become a major health problem worldwide, reaching epidemic proportions in many developing countries as well as in minority groups in the developed world (1, 2 ) . In the United States, the prevalence of diabetes diagnosed in people 20 -74 years of age increased from 4.9% in 1990 to 6 .5% in 1998 (3 ) . Worldwide projections suggest that Ͼ220 million people will have diabetes by the year 2010, and the majority of these (ϳ213 million) will have type 2 diabetes (4 ). In 1997, healthcare costs related to diabetes in the US were ϳ$100 billion, with one-half in direct costs; these costs also are projected to rise considerably (5 ) .
Type 1 diabetes is accompanied by long-term microand macrovascular complications, the primary causes of morbidity and mortality in these patients. Diabetic nephropathy, as the single most common cause of end-stage renal disease, accounts for more than one-third of all cases. Type 2 diabetes mellitus is associated with increased cardiovascular and overall mortality. In fact, type 2 diabetic patients diagnosed before 70 years of age have only 70% of the life expectancy of nondiabetic people (6, 7 ) . Epidemiological data suggest that classic cardiovascular risk factors, such as hypercholesterolemia, hypertension, and smoking, do not account for the excess risk of cardiovascular morbidity and mortality in type 2 diabetes mellitus. Thus, understanding the pathogenesis and preventing and/or ameliorating these long-term complications have been major goals of research in diabetes mellitus.
sugars to the nonprotonated free amino groups of proteins) changes the structure and function of several soluble and insoluble proteins in vivo and in vitro (8 -13 ) . Because cells and their extracellular matrix share a dynamic and reciprocal relationship (14 ) , modulations of matrix components by glycation leads to altered cell behavior, including changes in cell spreading, phosphorylation of key intracellular signaling molecules, and expression of extracellular matrix proteins and their modulators (15) (16) (17) . Extracellular matrix from diabetic patients is more extensively glycated than extracellular matrix from nondiabetic people. In addition, the accumulation of glycation products and the accompanying structural extracellular matrix modifications correlate with the development of functional complications of diabetes (18 -21 ) . These changes in tissue structure and function are slow and cumulative, producing a long time lag between the start of diabetes and the onset and progression of the complications.
Glycohemoglobin
Hemoglobin is one of many proteins that undergo nonenzymatic glycation, and glycohemoglobin (GHb) 1 is a general term for hemoglobin nonenzymatically glycated by glucose. Rahbar (22 ) first described GHbs in 1968 as diabetic hemoglobins. Potential glycation sites of the hemoglobin A molecule include the N-terminal amino acid valine of the four-polypeptide chains and all of the free ⑀-amino groups of lysine residues. The predominant glycation site is the N-terminal valine residue of the ␤ chain, which accounts for ϳ60% of bound glucose. Total GHb refers to all GHb species that are measured by affinity chromatographic methods (23 ) . Hemoglobin A 1 (HbA 1 ), which is more negatively charged than HbA, may be detected by cation-exchange chromatography and includes HbA 1a , HbA 1b , and HbA 1c , which are named in order of their elution from the column. Of these, HbA 1c represents the most prevalent glycated species and is defined by the IFCC as HbA irreversibly glycated at one or both N-terminal valines of the ␤ chains. To a lesser extent, other glucose molecules are bound to 1 or more of the 44 glycation sites at the ⑀-amino groups within the hemoglobin molecule or at the N-terminal valines of the ␣ chains (24, 25 ) .
Because erythrocytes are freely permeable to glucose, the rate of formation of GHb is directly proportional to the ambient glucose concentration in which the erythrocyte circulates and to the duration of exposure. In addition, because the postsynthetic modifications of HbA irreversibly form GHb, the GHb concentration constitutes a reliable, integrated measure of the average blood glucose concentration over the life spans of circulating red cells (i.e., 2-3 months). Clinical GHb testing became widely available in the early 1980s, and thus objective measurement of long-term glycemic status became possible (26 -29 ) .
Measurement of GHb, either as HbA 1c or as total GHb, is widely used in clinical practice to monitor glycemia in diabetic patients. The American Diabetes Association (ADA) recommends GHb testing at least twice a year in patients who have stable glycemic control and more frequently (quarterly assessment) in patients whose therapy has changed or who are not meeting glycemic goals. The ADA recommends that the goal of therapy should be a GHb concentration Ͻ7% and that treatment regimens should be reevaluated if GHb values are consistently Ͼ8%; these values apply only to assay methods that are certified as traceable to the Diabetes Control and Complications Trial (DCCT) reference method (30 -32 ) . GHb serves as a key predictor of the risk of developing diabetic complications. In addition, knowledge of GHb concentrations appears to alter the behavior of healthcare providers and/or patients, in turn improving glycemia and lowering GHb values (33 ) .
Glycohemoglobin and Diabetic Complications
Only in the last decade have the DCCT (32 ) In the DCCT, which included 1441 type 1 diabetic participants, the mean HbA 1c in the groups receiving intensive therapy was 7.2%, which reduced the risk of developing retinopathy in the primary prevention cohort by 76% and reduced the risk of progression of retinopathy in the secondary intervention cohort by 54%, compared with the conventionally treated group (mean HbA 1c , 9.1%) (32, 35 ) . In the UKPDS, 3867 newly diagnosed type 2 diabetic patients were followed over 10 years. coagulation (34 ) . Of 102 type 1 diabetic patients in the Stockholm Diabetes Intervention Study (SDIS) followed for 7.5 years, 27% of patients receiving intensive therapy (mean GHb, 7.1%) developed serious retinopathy compared with 52% of patients receiving conventional treatment (mean GHb, 8.5%) (36 ) . In WESTDR, with 1210 younger onset and 1780 older onset diabetic patients, HbA 1c at baseline was a significant predictor of incidence and progression of proliferative retinopathy after adjustment for duration of diabetes (37, 38 ) . HbA 1c concentrations (divided into both quartiles and deciles) correlated with a consistent increase in retinopathy from the lowest (5.4 -8.5%) to highest quartile (11.6 -20.8%) and lowest to highest decile with no evidence of a threshold effect. Furthermore, the WESTDR investigators estimated that a 1.5% decrease in HbA 1c would lead to a 24 -33% decrease in the 10-year incidence of proliferative retinopathy. Wu et al. (39 ) , who studied 137 type 2 diabetic patients for 5 years, found a 1.5-fold increased risk of retinopathy in patients with a high HbA 1c of 10.5% compared with patients with a lower HbA 1c of 6.9%. Henricsson et al. (40 ) studied 72 patients and demonstrated that each percentage increase in HbA 1c was associated with a 1.56-to 1.68-fold increased risk of retinopathy. These and other studies (32, 34 -42 ) are summarized in Table 1 .
nephropathy (table 2; figs. 1 and 2)
In the DCCT with the two cohorts combined, intensive therapy reduced the incidence of microalbuminuria (urinary albumin excretion Ն40 mg/24 h) by 39% and clinical grade albuminuria (urinary albumin excretion Ն300 mg/24 h) by 54% (32, 43 ) . In the UKPDS, intensive therapy was associated with a reduction in progression of albuminuria and a 67% risk reduction in the proportion of patients having a twofold increase in plasma creatinine (34 ) . Similar findings were found in the SDIS, with the difference in proportions between intensive and standard treatment being 16% (36 ) . In the Wisconsin cohort, followed by Klein (38 ) over a period of 10 years, 28% of all younger and 36% of all older patients developed gross proteinuria, and 7% of all younger and 2% of all older patients developed renal failure. In that study (38 ) , compared with patients in the lowest quartile, patients in the highest quartile of HbA 1c had a two-to fourfold increased risk of both proteinuria and renal failure. In a recent study by Ravid et al. in 1998 (44 ) , in which the authors followed 574 patients for 2-9 years, the risk of progression from microalbuminuria to macroalbuminuria was 18-fold greater in high vs low GHb groups. Tanaka et al. (45 ) , who studied 123 type 2 diabetic patients, found that the group that developed microalbuminuria showed a higher 6-year mean HbA 1c of 9.0% than the group that remained normoalbuminuric (8.1%). The HbA 1c concentration separating normo-from microalbuminuric patients was 8.5%. These and other studies (32, 34, 36, 38, (43) (44) (45) (46) are summarized in Table 2 . macrovascular disease/overall mortality (table 3) In the DCCT, intensive therapy reduced, although not significantly, the risk of macrovascular disease by 41%, from 0.8 events to 0.5 events per 100 patient-years (32 ) . In the UKPDS, the intensively treated group had a 10% lower risk for any diabetes-related death (P ϭ 0.34) and 6% lower risk for all-cause mortality (P ϭ 0.44) compared with the conventionally treated group; however, these differences were not statistically significant (34 ) . In the Wisconsin cohort studied by Klein (38 ) , the hazard ratio for dying was 1.9-fold greater for patients in the fourth quartile of HbA 1c concentrations, relative to the first quartile. Similarly, Ravid et al. (44 ) found that a high GHb was associated with a 15-fold greater risk of cardiovascular morbidity and mortality compared with low values. As recently reported in the Norfolk cohort of the Euro- The decrease in mean HbA 1c with intensive therapy or difference of mean GHb concentrations between the lowest and highest quartile was statistically significant: ¶, P Ͻ0.001; ‫,ء‬ P Ͻ0.0001. INT, intensive therapy; CONV, conventional therapy; pts, patients. Fig. 2 . Percentage of risk reduction for retinopathy and nephropathy after intensive therapy in the DCCT (32 ) and UKPDS (34 ) , or in patients with GHb concentrations in the lowest quartile in the WESTDR compared with the highest quartile (38 ) .
The risk reduction was statistically significant: ‫,ء‬ P Ͻ0.04; ‫,ءء‬ P Ͻ0.002; §, P Ͻ0.0031; ¶, P Ͻ0.0001.
pean Prospective Investigation of Cancer and Nutrition (EPIC), men with known diabetes clearly had increased mortality from all causes, from cardiovascular disease, and from ischemic disease (relative risks, 2.2, 3.3, and 4.2, respectively; P Ͻ0.001 independent of age and other risk factors) (47 ) . HbA 1c concentrations at baseline were a strong predictor of cardiovascular risk factors, cardiovascular events, stroke, and overall mortality in these and other studies (32, 34, 38, 39, 44, (47) (48) (49) (50) (51) (52) , as summarized in Table 3 .
Hypoglycemia
Although better glycemic control is clearly associated with decreased risk of development of diabetic complications, hypoglycemia is the major limiting factor for intensive therapy in all diabetic patients (both type 1 and type 2). In the DCCT and the UKPDS, the intensive treatment groups had a higher risk of hypoglycemia (32, 34 ) . However, the DCCT Research Group also demonstrated significant benefits of sustaining ␤-cell function with intensive treatment and thereby significantly reducing the risk of severe hypoglycemia (53 ) . In short, the benefits of intensive therapy must always be weighed against the greater risk of hypoglycemia.
Reversal of Diabetic Complications
Diabetic complications develop insidiously and are difficult to reverse. Although rapid reversal of early renal lesions (e.g., mesangial expansion) has been demonstrated within months in diabetic rats rendered normoglycemic by islet or whole pancreas transplantation (54, 55 ) , 5 years of normoglycemia with successful pancreas transplantation did not reverse established diabetic glomerular lesions in type 1 patients with their own kidneys (56 ) . Only after 10 years of normoglycemia in these same pancreas transplant recipients were glomerular and tubular lesions ameliorated, i.e., a reduction in the thickness of the glomerular and tubular basement membranes and diminished mesangial matrix volume were achieved (57 ) . Thus, even advanced lesions of diabetic nephropathy may be reversed, but only over a period of time (1 decade) approaching the duration of diabetes necessary to develop nephropathic lesions (1-2 decades) (20 ) .
Benefits of Improved Glycemic Control
All observations reviewed in this report clearly demonstrate the importance of improved glycemic control in preventing, delaying, or reversing complications in both 
Additional Uses of Glycohemoglobin
Increased GHb has been demonstrated to be a marker for cardiovascular risk factors, events, and mortality even in nondiabetic subjects ( 
Challenges Concerning the Measurement of Glycohemoglobin
Despite the overwhelming evidence that GHb measurements should be used to guide the therapy of diabetes, the test may be underutilized clinically. The ADA recommends measuring HbA 1c at least twice a year in diabetic patients with stable glycemic control and more frequently in patients who are not meeting glycemic goals (31 ). In addition, although the ADA Provider Recognition Program iterates specific goals for HbA 1c , in the ambulatory population ϳ25% of diabetic patients may fail to have GHb determinations completed even annually (66 ) . One major challenge in implementing these standards has been the multitude of analytical methods for GHb (Ͼ20), most of which measure different combinations of chemically modified hemoglobins. The National Glycohemoglobin Standardization Program (NGSP) and an IFCC working group have continuously improved the standardization of GHb measurements to ensure that all methods measuring GHb are comparable to the results from the DCCT. For example, more manufacturers pro- a In reports where the authors do not clearly specify whether ion-exchange or affinity methods were used, the most likely method has been specified according to the terminology used in reporting GHb results. b INT, intensive; CONV, conventional.
duce assays that have been certified by the NGSP as traceable to the DCCT reference method (67 ) . In the United States, recent College of American Pathologist surveys show that 95% of laboratories report HbA 1c and 5% report total GHb or HbA 1 . Overall, ϳ90% of the assay methods in the United States are NGSP certified. The ADA and the Health Care Financing Agency are working together in setting and trying to achieve therapeutic goals in the community (31 ). When specific numbers are set as goals for healthcare providers, standardization becomes even more critical. Although the procedure used in the DCCT has been proposed as the comparison method against which most assays should be standardized, there is no universally accepted reference method. For example, the HbA 1c result by ion-exchange HPLC reflects only 60% specificity because of ␤-N-deoxyfructosyl-Hb; i.e., Hb glycated at the NH 2 terminus of the ␤ chain (68 ) . Despite the challenges with GHb standardization, the studies reviewed here, irrespective of the different analytical methods used and the variation in the values for a "normoglycemic" reference population, clearly showed that poorer metabolic control was associated with an increased risk of micro-and macrovascular complications of diabetes mellitus.
Recent Advances in Estimation of Glycohemoglobin
Recently, procedures using electrospray ionization mass spectrometry (ESI-MS) have been developed as candidate (69, 70 ) , at low GHb concentrations, hemolysates from diabetic patients revealed higher ␤-chain to ␣-chain glycation, whereas at high GHb concentrations, multiple ␤-chain sites were glycated, accompanied by increasing ␣-chain glycation. In addition, Roberts et al. (69 ) demonstrated that even at the highest value analyzed for GHb, only a single glucose molecule was added to the multiple glycation sites. They also found reasonably good linear correlations of all established methods compared with ESI-MS, although the latter method generally reported a lower percentage of GHb than the separation methods. Kobold et al. (71 ) analyzed endoproteinase Glu-C digests of whole-blood samples.
Endoproteinase Glu-C cleaves N-terminal segments of the ␤ chains between the two glutamic acid residues at positions 6 and 7, with the resulting fragments containing only a single glycation site at the ␤-chain N-terminal valine. By this approach, interference by carbamylated and acetylated N-terminal species and by the dimer composed of a glycated ␣ chain and a nonglycated ␤ chain are excluded. In other words, HbA 1c as defined by the IFCC is actually measured. However, is it more important to determine glycation on only the ␤-chain N-terminal valine (which has been defined as HbA 1c by the IFCC working group) or to estimate all possible glycation sites in hemoglobin (i.e., the total glycated burden) as with the ESI-MS method without Glu-C digestion of the hemolysates? Overall, measurement of glycation at the N-terminal valine of the ␤ chain is more specific, and a proposed reference system demands an exact knowledge of the analyte to be measured. Alternatively, measurement of all potentially glycated sites might be clinically more relevant, especially at high GHb concentrations. All of these hold promise as candidate reference methods to yield a procedure to address the problem of standardization in GHb testing. However, mass spectrometric methods may not have a primary role in routine laboratory settings in the immediate future because of the expensive and sophisticated hardware and software, the modest throughput, and the technical knowledge required for accurate and reliable results. Because the development of complications is linked to the accumulation of glycation adducts in tissue proteins, any analytical method that serves as an index of the extent of glycation should clearly be used to guide therapy in diabetes. Although the ion-exchange method does not meet contemporary standards for accuracy, immensely valuable prognostic information has been gathered with this procedure over nearly 2 decades of observing the 1441 and 3867 subjects, respectively, in the DCCT and the UKPDS. Other important studies, both prospective and retrospective, have used either the ion-exchange method or have used methods that correlate to the DCCT method for estimation of GHb. It is clear that near-normal glycemic control is necessary to prevent the development and progression of complications. Moreover, because it is difficult to reverse complications, one cannot justify a clinical trial with another method to confirm the efficacy of glycemic control on diabetic complications, as demonstrated by the DCCT (32 ) and UKPDS (34 ) . From the results of these clinical trials, it would be unethical to initiate a new prospective trial with treatment groups having different degrees of glycemic control to test the efficacy of the new reference method for GHb. Therefore, regardless of the reference method(s) adopted, the HbA 1c concentrations measured in the DCCT and UKPDS will have to be related to values based on the new reference systems because the ESI-MS methods will yield lower values for GHb. Furthermore, this translation must be computationally and efficiently effected because adequate monitoring of glycemic control by GHb estimation is a necessary component of management for the patients and their healthcare providers. The transition to new standards much be completed with caution, i.e., only when the new method's efficacy can be compared with the ion-exchange method, a procedure used in two major trials and whose values reflect the contemporary clinical standard.
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